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Summary
 
CD4
 
1
 
 T cells play an important role in antitumor immune responses and autoimmune and in-
fectious diseases. Although many major histocompatibility complex (MHC) class I–restricted
tumor antigens have been identified in the last few years, little is known about MHC class II–
restricted human tumor antigens recognized by CD4
 
1
 
 T cells. Here, we describe the identifi-
cation of a novel melanoma antigen recognized by an human histocompatibility leukocyte an-
tigen (HLA)-DR1–restricted CD4
 
1
 
 tumor-infiltrating lymphocyte (TIL)1363 using a genetic
cloning approach. DNA sequencing analysis indicated that this was a fusion gene generated by
a low density lipid receptor (LDLR) gene in the 5
 
9
 
 end fused to a GDP-
 
l
 
-fucose:
 
b
 
-
 
d
 
-galacto-
side 2-
 
a
 
-
 
l
 
-fucosyltransferase (FUT) in an antisense orientation in the 3
 
9
 
 end. The fusion gene
encoded the first five ligand binding repeats of LDLR in the NH
 
2
 
 terminus followed by a new
polypeptide translated in frame with LDLR from the FUT gene in an antisense direction.
Southern blot analysis showed that chromosomal DNA rearrangements occurred in the
1363mel cell line. Northern blot analysis detected two fusion RNA transcripts present only in
the autologous 1363mel, but not in other cell lines or normal tissues tested. Two minimal pep-
tides were identified from the COOH terminus of the fusion protein. This represents the first
demonstration that a fusion protein resulting from a chromosomal rearrangement in tumor cells
serves as an immune target recognized by CD4
 
1
 
 T cells.
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T
 
he adoptive transfer of CTLs, derived from tumor-
infiltrating lymphocytes (TILs),
 
1
 
 along with IL-2 into
autologous patients with cancer resulted in the objective
regression of tumor, indicating that these CTLs could rec-
ognize cancer rejection antigens on tumor cells. In the last
few years, many tumor antigens recognized by CD8
 
1
 
 T cells
have been identified in melanomas as well as in other types
of cancers using a cDNA library expression system and di-
rect sequencing of peptides eluted from the tumor cell sur-
face (1–3). These findings led to several clinical trials using
peptides derived from the molecularly defined tumor anti-
gens recognized by CD8
 
1
 
 T cells. Although the first clini-
cal trial using a modified peptide derived from gp100 has
shown evidence of therapeutic efficacy for the treatment of
patients with metastatic melanoma and achieved a 42%
clinical response rate (4), increasing evidence has indicated
that optimal cancer vaccines require the participation of both
CD4
 
1
 
 and CD8
 
1
 
 T cells (5, 6). CD4
 
1
 
 T cells play a central
role in antitumor immune responses and autoimmune and
infectious diseases (7–10). Identification of antigens recog-
nized by CD4
 
1
 
 T cells is thus important for the develop-
ment of cancer vaccines and new strategies for the treat-
ment of autoimmune and infectious diseases.
CD4
 
1
 
 T cells recognize a peptide bound on MHC class
II molecules on the surface of APCs (11, 12). Attempts to
isolate antigenic peptides recognized by CD4
 
1
 
 T cells from
MHC class II–peptide complexes using a combination of
HPLC and mass spectrometric sequence analysis have been
unsuccessful due to the heterogeneous lengths of the anti-
genic peptides. The biochemical purification of antigenic
proteins from tumor cell lysates has been used successfully
(13), but this strategy largely depends on the abundance of
the Ag of interest and its efficient uptake by APCs. Tyro-
sinase is a human MHC class II–restricted melanoma Ag
recognized by CD4
 
1
 
 T cells, which was identified by test-
ing the reactivity of several candidate Ags pulsed onto
MHC class II–matched EBV-B cells (14). Because of these
 
1
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difficulties, much less is known about MHC class II–
restricted human tumor antigens recognized by CD4
 
1
 
 T
cells. To facilitate the identification of these MHC class II–
restricted antigens, we recently developed a novel genetic
approach to identifying MHC class II–restricted tumor an-
tigens. In this report, we describe the identification of a
new tumor antigen generated from a chromosomal rear-
rangement and recognized by CD4
 
1
 
 T cells.
 
Materials and Methods
 
Chemicals and Reagents.
 
The following chemicals and reagents
were used and were purchased from the sources indicated: RPMI
1640, AIM-V medium, Lipofectamine, and G418 (GIBCO BRL);
the eukaryotic expression vector pcDNA3.1 (Invitrogen); anti–
HLA-DR1 mAb (One Lambda); and anti-IgM antibody conju-
gated with FITC (Vector Labs., Inc.).
 
Cell Lines and Cultures.
 
CD4
 
1
 
 TILs were cultured from a
subcutaneous metastasis resected from patient 1363. T cell clones
or lines were grown in AIM-V medium containing 10% human
AB serum and rIL-2 (1,000 IU/ml; Chiron). Melanoma cell lines
and EBV-transformed B cell lines were maintained in RPMI
1640 with 10% FCS. COS-7, 293, 293IMDR1, and 293IMDR4
cell lines were grown in the DMEM containing 10% FCS. The T
cell clones or cloids were generated by limiting dilution methods
(at 1 cell/well) from the CD4
 
1
 
 TIL1363 cell line. After 12 d, the
T cell clones were expanded in AIM-V medium containing
6,000 IU/ml IL-2. To obtain an optimal expansion, we used the
OKT3 expansion method as previously described (15, 16). In
brief, on day 0, 5 
 
3
 
 10
 
4–5
 
 T cells were cocultured with HLA-
DR1
 
1
 
 PBLs (PBL/T cell ratio, 500:1) and 586 EBV B cells
(EBV/T cell ratio, 100:1) in 25 ml RPMI 1640 containing 11%
human sera, 30 ng/ml OKT3 antibody, and antibiotics. On day
1, IL-2 was added at a final concentration of 180 IU/ml. The
medium was changed with fresh medium containing 11% human
sera and 180 IU/ml IL-2 on day 5. The medium was then
changed every 3 d. On days 12–14, T cells were harvested,
counted, and cryopreserved.
Melanoma cell lines 397mel, 1088mel, 1359mel, 1363mel, and
1558mel and EBV-transformed B cell lines 586EBV, 1363EBV,
1359EBV, and 1558EBV were established in our laboratory and
cultured in RPMI 1640 containing 10% FCS.
 
cDNA Library Construction.
 
Total RNA was extracted from
1363mel using Trizol reagent from GIBCO BRL. Poly(A) RNA
was purified from total RNA by polyATract system (Promega
Corp.) and converted to cDNA using a cDNA construction kit
(GIBCO BRL) with an oligo-dT primer. To create an invariant
chain (Ii) fusion library, an Ii fragment (amino acids 1–80) was in-
serted into a mammalian expression vector, pEAK8 (Edge Bio-
System), to generate a pTi80 vector. The cDNA inserts were
then ligated to pTi80, and cDNA libraries were electroporated
into DH10B cells (GIBCO BRL). Plasmid DNAs for cDNA li-
brary pools were prepared from bacteria, each consisting of 
 
z
 
100
cDNA clones.
 
cDNA Library Screening and GM-CSF Secretion Assay.
 
DNA
transfection and GM-CSF assays were performed as previously
described (15, 16). In brief, 200 ng of cDNA pools was mixed
with 2 
 
m
 
l of Lipofectamine in 100 
 
m
 
l of serum-free DMEM for
15–45 min. The DNA/Lipofectamine mixture was then added to
the 293IMDR1 (5 
 
3
 
 10
 
4
 
)
 
 
 
cells and incubated overnight. The fol-
lowing day, cells were washed twice with AIM-V medium.
CD4
 
1
 
 TIL1363 cells were added at a concentration of 5 
 
3
 
 10
 
4
 
cells/well in AIM-V medium containing 120 IU/ml of IL-2. Af-
ter 18–24 h of incubation, 100 
 
m
 
l of supernatant was collected
and GM-CSF concentration was measured in a standard ELISA
assay (R&D Systems). For testing peptide recognition, 1363EBV
cells were incubated with peptides at 37
 
8
 
C for 90 min, then
washed three times with AIM-V medium containing 120 IU/ml
of IL-2. T cells were added and incubated for an additional 18–
24 h. In some experiments, peptides were directly incubated with
CD4
 
1
 
 TIL1363 for 90 min, then washed three times. 5 
 
3
 
 10
 
4
 
 T
cells were then mixed with the peptide-binding T cells and incu-
bated for an additional 18–24 h. 100 
 
m
 
l of supernatant was col-
lected for GM-CSF assay.
 
Northern Blot Analysis.
 
Total RNA was isolated using Trizol
reagent from GIBCO BRL. Total RNA from human normal tis-
sue was purchased from Clontech. 20 
 
m
 
g of total RNA was sub-
jected to electrophoresis in a 1.2% formaldehyde agarose gel and
transferred to a nylon membrane. DNA fragments of the LDLR-
FUT (low density lipid receptor–GDP-
 
l
 
-fucose:
 
b
 
-
 
d
 
-galactosidase
2-
 
a
 
-
 
l
 
-fucosyltransferase) fusion gene for probe A, the LDLR-speci-
fic probe B, and the FUT-specific probe C were labeled with
[
 
a
 
-
 
32
 
P]CTP by the random priming method. Prehybridization
and hybridization were performed according to the QuickHyb
protocol (Stratagene). Membranes were washed twice with 2
 
3
 
SSC/0.1% SDS at room temperature for 15 min and twice with
0.1
 
3
 
 SSC/0.1% SDS at 60
 
8
 
C for 30 min. The autoradiography
was performed at 
 
2
 
70
 
8
 
C.
 
Southern Blot Analysis.
 
Genomic DNAs were isolated from
tumor and EBV-B cell lines using a DNA Isolation Kit (Boehringer
Mannheim), and digested with BamHI, HindIII, or EcoRI. The
digested DNA fragments were separated from an 0.8% agarose
gel, and transferred to nitrocellulose membrane. Membranes
were prehybridized for 1 h, then hybridized with [
 
a
 
-
 
32
 
P]CTP–
labeled probes using QuickHyb solution (Stratagene). After wash-
ing twice with 2
 
3
 
 SSC/0.1% SDS at room temperature for 15
min and twice with 0.1
 
3
 
 SSC/0.1% SDS at 65
 
8
 
C for 15 min, the
membrane was exposed to an x-ray film at 
 
2
 
70
 
8
 
C.
 
5
 
9
 
 RACE.
 
Total RNA was extracted from tumor cell lines
as described above. 5
 
9
 
 RACE (rapid amplification of cDNA ends)
was performed according to the manufacturer’s procedure
(GIBCO BRL). PCR products were cloned into the TA cloning
vector (Invitrogen). Recombinant DNA was prepared and used
for DNA sequencing analysis using an automatic sequencer (Ap-
plied Biosystems, Inc.).
 
Peptides Synthesis and T Cell Epitopes.
 
The peptides were syn-
thesized by a solid-phase method using a peptide synthesizer
(model AMS 422; Gilson Co., Inc.). Some peptides were purified
by HPLC and had 
 
.
 
98% purity. The mass of some peptides was
confirmed by mass spectrometry analysis. Identification and char-
acterization of peptides reactive with CD4
 
1
 
 TIL1363 were con-
ducted as previously described (15, 16).
 
Results
 
Recognition of Autologous Tumor Cells by HLA-DR–restricted
CD4
 
1
 
 T Cells.
 
CD4
 
1
 
 TIL1363 cells were generated from
a melanoma metastasis of patient 1363 and were found to
recognize the autologous tumor cell line 1363mel, but did
not recognize autologous EBV-B cells (1363EBV), other
EBV-B cells, MHC class II–matched or –mismatched tumor
cell lines, nor 293-expressing DR molecules (Fig. 1 A).
Furthermore, CD4
 
1
 
 TIL1363 cells were capable of recog-
nizing cell lysates of 1363mel pulsed onto DR-matched 
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EBV B cells, but did not recognize cell lysates derived from
other tumors, EBV-B cells, or fibroblasts (data not shown).
These results suggested that TIL1363 recognized a unique
tumor antigen from the autologous tumor. T cell recogni-
tion was specifically blocked by an mAb against HLA-DR,
but not by mAbs against HLA-DQ or MHC class I (Fig.
1 B). FACS
 
®
 
 analysis of 1363mel indicated that only HLA-
DR1 was expressed in 1363mel (Fig. 1 C), which was con-
sistent with the result of HLA genotyping analysis. These
results suggested that CD4
 
1
 
 TIL1363 recognized a tumor
antigen presented by HLA-DR1.
 
Identification of a Fusion Protein Recognized by CD4
 
1
 
TIL1363.
 
Although many MHC class I–restricted tumor
antigens have been identified by the expression cloning ap-
proach, this conventional expression approach cannot be
applied to isolating genes encoding MHC class II–restricted
Ags, because of differences in the endogenous and exoge-
nous Ag presentation pathways. It has been reported that
Ii-fused antigens could be endogenously processed and pre-
sented to CD4
 
1
 
 T cells (17–20). Our strategy is to target Ii
fusion proteins translated from the Ii fusion library to the
endosomal/lysosomal compartment for efficient antigen
processing and presentation. Although EBV-B and den-
dritic cells are professional APCs, they were poorly trans-
fectable and cDNA libraries could not be efficiently intro-
duced into these APCs. Thus, we generated 293IMDR1
cells by introducing cDNAs encoding DR
 
a
 
, DR
 
b
 
, DMA,
DMB, and Ii into 293 cells, a transformed human kidney
embryonic cell line, and used them as “professional” APCs.
This novel approach has been successfully used to isolate a
mutated CDC27 as an MHC class II–restricted tumor anti-
gen recognized by CD4
 
1
 
 T cells (20a).
To isolate the gene encoding a tumor antigen recog-
nized by CD4
 
1
 
 TIL1363, we constructed a cDNA library
with the fusion of a targeting sequence of Ii in the 5
 
9
 
 end of
cDNAs derived from 1363mel. cDNA subpools with
 
z
 
100 cDNA clones per pool were prepared. The 1363
cDNA library was introduced into 293IMDR1 expressing
DMA, DMB, Ii, and DR1 molecules. After screening a to-
tal of 3.5 
 
3
 
 10
 
5
 
 cDNA clones, we identified 
 
.
 
10 positive
cDNA pools that conferred T cell recognition by CD4
 
1
 
TIL1363 when transfected into 293IMDR1. The individ-
ual positive clones were then isolated from the positive
cDNA pools and tested for recognition by CD4
 
1
 
 TIL1363.
Representative data is shown in Fig. 2.
DNA sequencing analysis showed that cDNA clone 7
encoded a fusion protein consisting of 363 amino acids
(Fig. 3). A database search revealed that the first 880 nucle-
otides were identical to a published sequence of the LDL
receptor (21, 22). However, the DNA sequence in the 3
 
9
 
end of cDNA clone 7 was found to be identical to the pre-
viously published sequence of FUT with the exception of a
one-nucleotide (G) deletion at position 1049 (23). Further-
more, the LDLR sequence in the 5
 
9
 
 end of the cDNA was
fused to the intron/exon 3 of the FUT sequence in an anti-
Figure 1. Recognition of the autologous melanoma cell line by CD41 TIL1363. (A) Specific antitumor recognition of CD41 TIL1363. TIL1363 rec-
ognized the autologous 1363mel, but did not recognize autologous 1363EBV, other EBV-B cell lines, or allogeneic melanoma cell lines, nor 293-derived
cell lines. 1558mel shared the DR molecule b1*0101 with 1363mel. T cell recognition was evaluated based on GM-CSF release from CD41 TIL1363.
(B) HLA restriction of T cell recognition. CD41 TIL1363 cells were cocultured with autologous 1363mel cells in the presence or absence of various
anti-MHC antibodies. GM-CSF release was determined after an 18-h incubation. T cell recognition of 1363mel was specifically blocked by an anti-DR
antibody, but not by anti–MHC class I or anti-DQ antibodies. HLA genotyping of 1363mel was HLA-DR b1*0101. (C) FACS® analysis of 1363mel and
TIL1363 for HLA-DR1 expression.
Figure 2. Screening of a
cDNA library from RNA of
1363mel using CD41 TIL1363.
After screening 2.1 3 105
Ii-cDNA library clones gener-
ated from 1363mel RNA, posi-
tive cDNA pools were identified
based on GM-CSF release from
CD41 TIL1363. CD41 TIL1363
recognized 293IMDR1 trans-
fected with the cDNA clone 7,
but not with a control cDNA or
green fluorescence protein. Rec-
ognition of 1363mel by TIL1363
was used as a positive control.1662 Novel MHC Class II–restricted Tumor Antigen
sense orientation such that the translational reading frame
of the LDLR fusion protein continued for an additional
131 amino acids until a stop codon was reached. Therefore,
the LDLR-FUT fusion protein contained the first five
ligand binding repeats of LDLR followed by a novel poly-
peptide of 131 amino acids at the COOH terminus. A
database search did not reveal any sequence homologue to
the 131 amino acid polypeptide.
The Fusion cDNA Encoded a Secretory Protein. To con-
firm if T cell recognition was restricted by HLA-DR1, the
cDNA clone 7 was transfected into both 293IMDR1 and
293IMDR4 and then tested for recognition by CD41
TIL1363. To our surprise, CD41 TIL1363 cells were capa-
ble of recognizing both HLA-DR1 and DR4 positive cell
lines transfected with cDNA clone 7, but not with other
control cDNA clones (data not shown). FACS® analysis re-
vealed that TIL1363 expressed a high level of HLA-DR1
molecules on the cell surface, suggesting that these T cells
may function as APCs (Fig. 1 C). To further explore how
TIL1363 recognized an antigen expressed by 293IMDR4
cells lacking DR1 molecules, we tested the possibility that
T cells may capture an antigen from cell supernatants of
cells transfected with cDNA clone 7, and process and
present antigenic peptides to each other. Results presented
in Fig. 4 showed that CD41 TIL1363 cells were capable of
recognizing an antigen derived from the cell culture super-
natants of COS-7, 293, and 293IMDR4 cells transfected
with cDNA clone 7 and supernatants from 1363mel. Rec-
ognition of the supernatants by CD41 TIL1363 cells were
blocked by an anti-DR antibody, but not by a control anti-
body. Treatment of the cDNA clone 7–transfected COS-7,
293, and 293IMDR4 cells with the fixative agent PFA
alone or PFA combined with the anti-DR antibody com-
pletely abrogated the ability of conferring T cell recogni-
tion (Fig. 4), suggesting that blocking antigen secretion
from cells transfected with cDNA clone 7 abolished anti-
gen recognition by T cells. T cell recognition of 1363mel
by CD41 TIL1363 was partially inhibited by PFA. This
may be due to the existence of different subsets of CD41 T
cells in the TIL1363 population that recognized additional
antigens presented by 1363mel. These results indicated that
COS-7, 293, and 293IMDR4 cells transfected with cDNA
clone 7, as well as the untransfected 1363mel, secreted the
LDLR-FUT fusion protein into the culture medium,
which was in turn presented by MHC class II–positive T
cells to themselves.
Generation of a Unique Fusion Tumor Antigen by Chromo-
somal Rearrangement. To determine whether the fusion
protein was a consequence of a chromosomal rearrange-
ment, we did Southern blot analysis using the LDLR-FUT
fusion cDNA as probe A (Fig. 5 A). No difference was
found in the DNA band pattern of 1363mel genomic DNA
digested with either HindIII or EcoRI, compared with ge-
nomic DNA derived from other cell lines digested with the
same enzymes. However, an additional band was observed
in 1363mel genomic DNA digested with BamHI when
compared with the DNA patterns of 293, SK23, 1359mel,
624mel, and 586mel (Fig. 5 B). These results suggested that
a DNA rearrangement occurred in 1363mel. To further
evaluate if the fusion cDNA was expressed in 1363mel,
Northern blot analyses were performed. Two unique bands
were detected only in 1363mel by the fusion cDNA probe
A (Fig. 5 C). No corresponding bands were observed from
any other tumor cell lines or normal tissues tested (Fig. 5 C).
Figure 3. The nucleotide and amino acid sequences of the human
LDLR-FUT fusion gene. The numbering of amino acid sequence of
the LDLR-FUT protein starts with the first amino acid Met. The 59 un-
translated region was isolated by 59 RACE and was found to be identical
to the previously published sequence of LDLR after sequencing analysis.
The fusion junction between LDLR and FUT was indicated by an arrow.
The EMBL/GenBank/DDBJ accession number for the fusion gene is
AF117899.1663 Wang et al.
Using specific DNA probes derived from either LDLR
cDNA or FUT (Fig. 5 A), we found that probe B, which
was specific for LDLR, detected two identical bands ob-
served in the 1363mel RNA sample using probe A, but not
in the RNA samples of 1363EBV, 1359mel, or 293 (Fig.
5 D). However, the DNA probe C, which was specific for
FUT, only detected a single band, suggesting that the 59
portion of two RNAs from 1363mel was the same and
contained the LDLR fragment, but the 39 portion was dif-
ferent, which might result from an alternative splicing.
Both LDLR and FUT had been mapped on human
chromosome 19, but LDLR was located on 19p and FUT
on 19q (24, 25). In Fig. 6 we propose a possible gene
fusion resulting from a chromosomal rearrangement. The
LDLR gene was fused to the FUT gene in an opposite di-
rection to LDLR. The fusion junction was located be-
tween the exon 4 of LDLR and the intron/exon 3 of FUT.
Two RNA species were generated, probably by an alterna-
tive splicing.
Characterization of Peptides Recognized by CD41 TIL1363.
To determine the antigenic epitopes recognized by CD41
TIL1363, we first tested whether CD41 TIL1363 recog-
nized 293IMDR1 transfected with the wild-type LDLR
cDNA. No T cell recognition was observed with the LDLR-
transfected 293IMDR1, suggesting that T cell epitopes
were located either in the new polypeptide translated from
Figure 4. Recognition of the secreted fu-
sion protein by CD41 TIL1363. COS-7,
293, and 293IMDR4 were transfected with
cDNA clone 7. 48 h after transfection, cell
supernatants were harvested from the trans-
fected COS-7, 293, and 293IMDR4 cells as
well as the untransfected 1363mel, and co-
cultured with CD41 TIL1363 for an addi-
tional 18–24 h. Antibody blocking was
done by the pretreating supernatants or
transfected COS-7, 293, and 293IMDR4
cells with either anti-DR or control anti-
bodies for 30 min before coculture with
CD41 TIL1363. To block the secretion of
the LDLR-FUT from the cDNA clone
7–transfected cells or 1363mel, these trans-
fectants and 1363mel were treated with 1%
PFA for 20 min, followed by three time
washes with PBS. CD41 TIL1363 cells were added and incubated for 18–24 h. Supernatants were used to measure GM-CSF release from CD41
TIL1363. CD41 TIL1363 reacted with 1363mel and the cDNA clone 7–transfected cells and their supernatants. T cell recognition could be blocked
with an anti-DR antibody.
Figure 5. Northern and
Southern blot analysis of ge-
nomic DNAs derived from dif-
ferent tumor cell lines. (A) A
schematic presentation of the
LDLR-FUT cDNA and probes
used for Southern and Northern
blot analyses. (B) Southern blot
analysis of genomic DNAs from
293 and melanoma cell lines.
Genomic DNAs were digested
with HindIII (H), BamHI (B), or
EcoRI (R), and separated on a
0.8% agarose gel. After transfer
to a membrane, DNA bands
were detected with a 32P-labeled
probe A. In addition to bands
seen in all cell lines, 1363mel
displayed an additional band
indicated by an arrow when di-
gested with BamHI. (C) North-
ern blot analysis of the LDLR-
FUT RNA transcripts in normal
human tissues and tumor cell
lines. Two distinct RNA bands
were detected in 1363mel RNA,
but not in RNA from other tu-
mor cell lines or normal tissues.
(D) Northern blot analysis of RNA samples using three different probes. Probe A was used to detect the whole fusion cDNA; probe B was specific for
the detection of LDLR transcript; and probe C was specific for the intron 1 sequence of FUT gene. Hybridization of blots with the probe A or B de-
tected two RNA bands in 1363mel, but not in other cell lines. However, only a single band was seen in 1363mel when hybridized with the probe C.1664 Novel MHC Class II–restricted Tumor Antigen
the sequence of FUT in an antisense direction or in the
junction region of the fusion protein.
34 15-mer peptides overlapping by eight amino acids
were synthesized based on the predicted amino acid se-
quence of the new polypeptide derived from the FUT se-
quence, and were tested for T cell recognition. Two of
these peptides were found to be recognized by CD41
TIL1363 (Fig. 7). These two peptides shared eight amino
acids (WRRAPAPG). Further truncations of the peptides
from either the NH2 or COOH terminus defined Trp (W)
at amino acid position 315 and Ala (A) at amino acid posi-
tion 320 as critical amino acids required for T cell recogni-
tion (Fig. 8 A). All the peptides containing the core se-
quence WRRAPA were recognized by CD41 TIL1363.
One 9-mer peptide LRFP312–320 (PVTWRRAPA), the
shortest peptide used in this experiment, was found to be ac-
tive in the stimulation of T cells (Fig. 8 A). Further trunca-
tions of this 9-mer peptide LRFP312–320 from the NH2 termi-
nus resulted in a loss of the ability to stimulate CD41
TIL1363 for GM-CSF release (data not shown). We also
tested T cell recognition of several truncated forms of the
15-mer peptide (WRRAPAPGAKA) from the COOH ter-
minus, and found that the shortest active peptide was the
9-mer peptide LRFP315–323 (WRRAPAPGA) (Fig. 8 B).
Therefore, these studies defined two 9-mer peptides,
LRF312–320 and LRFP315–323, recognized by CD41 TIL1363.
These two peptides shared a core sequence WRRAPA, and
Trp (W) at amino acid position 315 may serve as the P1 an-
chor residue for MHC binding, conforming to the HLA-
DR1 binding motif (26). The minimal peptide length is
9-mer, and peptides shorter than 9-mer failed to activate
CD41 TIL1363 for GM-CSF release even though they con-
tained the core sequence (Fig. 8 B). Peptide titration experi-
ments showed that both LRFP312–320 and LRFP315–323 pep-
tides exhibited a very similar peptide binding avidity to DR1
and could be detected by T cells at 100 ng/ml peptide con-
centration (Fig. 8 C).
Discussion
In this study we identified a novel tumor antigen recog-
nized by CD41 TIL1363 using a novel genetic strategy.
Although a biochemical approach has been used to identify
MHC class II–restricted tumor antigens, it is limited to the
CD41 T cells that are capable of recognizing tumor lysates
pulsed onto APCs such as EBV B cells. Several CD41 T
cell lines established in our laboratory recognized whole tu-
mor cells, but did not recognize cell lysates of autologous
tumor due to either low amounts of a particular antigen or
low efficient uptake by APCs (data not shown). We re-
cently cloned a mutated CDC27 as a tumor antigen recog-
nized by CD41 TIL1359 using this novel cloning strategy
(20a). Here, we demonstrate that a secreted protein en-
coded by a LDLR-FUT fusion cDNA is a tumor antigen
recognized by CD41 TIL1363. Despite the fact that a spe-
Figure 6. A schematic presentation of a chromosomal rearrangement
between LDLR and FUT. LDLR is located in 13p and FUT in 13q of
human chromosome 19. Only the first 5 exons of LDLR (total 18 exons)
and exons 2 and 3 of FUT were shown with their own promoters. Chro-
mosomal rearrangement resulted in the fusion between LDLR and FUT.
The DNA sequence of the fusion RNA 1 was identical to that shown in
Fig. 3. DNA sequence of the fusion RNA 2 was a variant of RNA 1,
which lacked the intron 1 sequence of FUT based on the Northern blot
analysis shown in Fig. 5.
Figure 7. Identification of peptides recognized by CD41 TIL1363
from the fusion protein. 34 15-mer peptides overlapping by 8 amino acids
were synthesized, and verified by mass spectrometry analysis. These pep-
tides were pulsed onto 1363EBV B cells for 90 min followed by three
washes. T cells were added, and after incubation for 18–24 h, GM-CSF
release was measured to identify the reactive peptides.1665 Wang et al.
cial cell line expressing MHC class II was not required in
this case, this genetic approach can be useful for the isola-
tion of genes encoding MHC class II–restricted tumor anti-
gens recognized by CD41 T cells.
The LDLR-FUT fusion gene was generated by a chro-
mosomal rearrangement as evidenced by our Southern and
Northern blot analyses (Fig. 3). Human LDL receptor is a
cell surface glycoprotein that regulates plasma cholesterol
levels. The ligand-binding domain of LDLR comprises
seven imperfect repeats in the extracellular region of the
protein. Each domain consists of z40 amino acids. LDL
receptors specifically bind LDL, the receptor–lipoprotein
complex is internalized by the cells via coated pits and vesi-
cles, and the entire LDL particle is delivered to lysosomes,
where it is disassembled by enzymatic hydrolysis, releasing
cholesterol for further cellular metabolism (24). More than
250 LDLR mutations including deletions, insertions, and
single point mutations have been reported to affect LDLR
function associated with familial hypercholesterolemia (24).
The FUT gene product regulates the expression of the H
antigen mainly on erythrocyte membranes. Koda et al. re-
ported that the FUT gene was expressed in gastric cancer
and ovarian cancer cells (23). Although the fusion protein
may still have the ability to bind LDL, we do not know the
biological significance of the fusion protein resulting from a
chromosomal rearrangement in 1363mel at this time.
There were several unique features associated with the
fusion antigen. (a) To our knowledge, this is the first report
that a secretory protein functions as a tumor antigen recog-
nized by CD41 T cells. Most antigens identified as MHC
class I–restricted tumor antigens are membrane proteins
and the previously identified MHC class II–restricted tu-
mor antigen, tyrosinase, is a membrane protein as well (14).
(b) It was previously reported that CTLs could be gener-
ated in vitro against the junction region of an oncogenic
fusion protein resulting from a chromosomal translocation
(27, 28). We show here that natural CD41 T cells from the
patient 1363 were capable of recognizing a melanoma anti-
gen consisting of a fusion protein, which allowed us to
detect a chromosomal rearrangement in chromosome 19 in
1363mel. The chromosomal rearrangement observed may
be a consequence of intrachromosomal recombination be-
tween the Alu repeats in the LDLR and FUT genes (24).
Lehrman et al. reported that deletions in the LDLR gene
by recombination of Alu repeats produced a truncated, se-
creted LDLR protein (29). (c) DR1-positive TIL1363 cells
were capable of presenting the LDLR-FUT fusion protein
to each other though it is not clear whether the fusion pro-
tein directly bound to the DR1 molecules on TIL1363 for
recognition. Alternatively, TIL1363 may capture the anti-
gen from the culture medium and process and present it to
each other by the exogenous antigen presentation pathway.
Our results indicate that CD41 TIL1363 recognized a
unique fusion antigen expressed in 1363mel (Fig. 1). Sev-
eral CD41 TILs have been established and characterized
in our laboratory. Most CD41 TILs recognized unique an-
tigens, but not nonmutated shared antigens, as is the case
for the majority of the MHC class I–restricted tumor anti-
gens recognized by CD81 CTLs that have been character-
ized (1–3). Tyrosinase is the only shared human melanoma
antigen identified thus far and is recognized by an HLA-
DR4–restricted CD41 TIL1088 (14). Pieper et al. reported
a mutated triosephosphate isomerase as a tumor antigen
recognized by CD41 TIL1558 (30). The point mutation of
triosephosphate isomerase created a T cell epitope that re-
quired a lower peptide concentration necessary for T cell
reactivity compared with the wild-type peptide. Recently,
we identified a mutated CDC27 as a tumor antigen recog-
nized by a DR4-restricted CD41 TIL1359 (20a). CDC27 is
an important component of the anaphase promoting com-
plex and plays a role in cell cycle regulation (31, 32). Inter-
estingly, the mutation itself in CDC27 did not constitute a
T cell epitope, rather it affected the posttranslational modi-
fication (phosphorylation) and protein trafficking, which
led to targeting of the mutated CDC27 protein to the
MHC class II presentation pathway. Peptides identified
Figure 8. Characterization of the anti-
genic peptides recognized by CD41
TIL1363. (A) Truncated forms of the pep-
tides were synthesized based on the peptide
sequence identified as reactive in Fig. 7, and
tested for T cell recognition. A core peptide
sequence (WRRAPA) was defined based
on T cell recognition. A 9-mer peptide was
identified as a minimal antigenic determi-
nant required for T cell reactivity. (B) Fur-
ther truncations of the reactive peptides
were synthesized to define the minimal
peptide determinant. 1363mel and 1359mel
were used as positive and negative controls,
respectively. (C) T cell secretion of GM-
CSF in response to peptide stimulation was
measured. LRFP312–320 (j) and LRFP315–323
(m) peptides exhibited a similar avidity for
T cell recognition. Background release of
GM-CSF by TIL1363 cultured with
1363EBV B cells in the absence of peptide
was undetectable.1666 Novel MHC Class II–restricted Tumor Antigen
from the LDLR-FUT fusion by CD41 TIL1363 cells were
located in the new polypeptide translated from the FUT
sequence in an antisense orientation. These T cell epitopes
were present in the 1363mel tumor cells, but not in the
normal cells. The requirement for peptides to be rec-
ognized by CD41 TIL1363 was the antigenic peptides
containing a core sequence (WRRAPA) with a minimal
length of 9 residues.
Although many tumor cells are MHC class II negative,
the specific role of CD41 T cells in antitumor immunity has
been demonstrated in a MHC class II–negative tumor model
(33). Moreover, in addition to providing help for CD81
CTLs (34), CD41 T cells may play a far broader role in or-
chestrating the host response to tumor (35) and autoimmune
diseases (36, 37). Our studies indicate the importance of
incorporating CD41 reactive antigens in immunotherapy
strategy. Definition of these MHC class II–presented anti-
gens may provide new opportunities for developing more
effective immunotherapies against cancer.
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